Synonyms: AZD-5305 | AZD5305 | example 4 [WO2021013735]
Compound class:
Synthetic organic
Comment: Saruparib (AZD5305) is a novel PARP1-selective inhibitor that was developed as an oncology therapeutic [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
AZD5305 is under clinical evaluation for efficacy against solid tumours. It is being considered as a monotherapy and in combination with established anti-cancer therapies. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | Phase 1 Interventional | AstraZeneca |